1
|
Goldstein KM, Zullig LL, Andrews SM, Sperber N, Lewinski AA, Voils CI, Oddone EZ, Bosworth HB. Patient experiences with a phone-based cardiovascular risk reduction intervention: Are there differences between women and men? PATIENT EDUCATION AND COUNSELING 2021; 104:2834-2838. [PMID: 33838939 DOI: 10.1016/j.pec.2021.03.027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Revised: 02/16/2021] [Accepted: 03/24/2021] [Indexed: 06/12/2023]
Abstract
OBJECTIVES To explore gender-based differences in experiences with a telehealth-delivered intervention for reduction of cardiovascular risk. METHODS We conducted 23 semi-structured qualitative interviews by telephone with 11 women and 12 men who received a 12-month, pharmacist-delivered, telephone-based medication and behavioral management intervention. We used content analysis to identify themes. RESULTS We identified three common themes for both men and women: ease and convenience of phone support, preference for proactive outreach, and need for trust building in the context of telehealth. While both genders appreciated the social support from the intervention pharmacist, women voiced appreciation for accountability whereas men generally spoke about encouragement. CONCLUSIONS Rapport building may differ between telehealth and in-person healthcare visits; our work highlights how men and women's experiences can differ with telehealth care and which can inform the development of future, purposeful rapport building activities to strengthen the clinician-patient interaction. PRACTICE IMPLICATIONS Clinicians should seek opportunities to provide frequent and routine support for patients with chronic disease. Telehealth interventions may benefit from gender-specific tailoring of social support.
Collapse
Affiliation(s)
- K M Goldstein
- Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, Durham, NC, USA; Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
| | - L L Zullig
- Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, Durham, NC, USA; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA
| | - S M Andrews
- Genomics, Bioinformatics, and Translational Research Center, RTI International, Durham, NC, USA
| | - N Sperber
- Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, Durham, NC, USA; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA
| | - A A Lewinski
- Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, Durham, NC, USA; School of Nursing, Duke University, Durham, NC, USA
| | - C I Voils
- William S Middleton Memorial Veterans Hospital, Madison, NC, USA; Department of Surgery, University of Wisconsin School of Medicine & Public Health, Madison, NC, USA
| | - E Z Oddone
- Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, Durham, NC, USA; Department of Medicine, Duke University School of Medicine, Durham, NC, USA
| | - H B Bosworth
- Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, Durham, NC, USA; Department of Medicine, Duke University School of Medicine, Durham, NC, USA; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA; School of Nursing, Duke University, Durham, NC, USA; Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA; Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Center for the Study of Aging and Human Development, Duke University School of Medicine, Durham, NC, USA
| |
Collapse
|
2
|
Lõiveke P, Marandi T, Ainla T, Fischer K, Eha J. Adherence to recommendations for secondary prevention medications after myocardial infarction in Estonia: comparison of real-world data from 2004 to 2005 and 2017 to 2018. BMC Cardiovasc Disord 2021; 21:505. [PMID: 34670499 PMCID: PMC8527758 DOI: 10.1186/s12872-021-02321-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 09/17/2021] [Indexed: 02/06/2023] Open
Abstract
Background Relatively high rates of adherence to myocardial infarction (MI) secondary prevention medications have been reported, but register-based, objective real-world data is scarce. We aimed to analyse adherence to guideline-recommended medications for secondary prevention of MI in 2017 to 2018 (period II) and compare the results with data from 2004 to 2005 (period I) in Estonia.
Methods Study populations were formed based on data from the Estonian Health Insurance Fund’s database and on Estonian Myocardial Infarction Register. By linking to the Estonian Medical Prescription Centre database adherence to guideline-recommended medications for MI secondary prevention was assessed for 1 year follow-up period from the first hospitalization due to MI. Data was analysed using the defined daily dosages methodology. Results Total of 6694 and 6060 cases of MI were reported in periods I and II, respectively. At least one prescription during the follow up period was found for beta-blockers in 81.0% and 83.5% (p = 0.001), for angiotensin converting enzyme inhibitor/angiotensin II receptor blocker (ACEi/ARB) in 76.9% and 66.0% (p < 0.001), and for statins in 44.0% and 67.0% (p < 0.001) of patients in period I and II, respectively. P2Y12 inhibitors were used by 76.4% of patients in period II. The logistic regression analysis adjusted to gender and age revealed that some drugs and drug combinations were not allocated similarly in different age and gender groups. Conclusions In Estonia, adherence to MI secondary prevention guideline-recommended medications has improved. But as adherence is still not ideal more attention should be drawn to MI secondary prevention through systematic guideline implementation.
Collapse
Affiliation(s)
- Piret Lõiveke
- Department of Cardiology, University of Tartu, Tartu, Estonia. .,Centre of Cardiology, North Estonia Medical Centre, 19 J. Sütiste Str, 13419, Tallinn, Estonia.
| | - Toomas Marandi
- Department of Cardiology, University of Tartu, Tartu, Estonia.,Centre of Cardiology, North Estonia Medical Centre, 19 J. Sütiste Str, 13419, Tallinn, Estonia.,Quality Department, North Estonia Medical Centre, Tallinn, Estonia
| | - Tiia Ainla
- Department of Cardiology, University of Tartu, Tartu, Estonia.,Centre of Cardiology, North Estonia Medical Centre, 19 J. Sütiste Str, 13419, Tallinn, Estonia
| | - Krista Fischer
- Institute of Mathematics and Statistics, University of Tartu, Tartu, Estonia
| | - Jaan Eha
- Department of Cardiology, University of Tartu, Tartu, Estonia.,Heart Clinic, Tartu University Hospital, Tartu, Estonia
| |
Collapse
|
3
|
Buja A, Caberlotto R, Pinato C, Mafrici SF, Bolzonella U, Grotto G, Baldovin T, Rigon S, Toffanin R, Baldo V. Health care service use and costs for a cohort of high-needs elderly diabetic patients. Prim Care Diabetes 2021; 15:397-404. [PMID: 33358612 DOI: 10.1016/j.pcd.2020.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 11/16/2020] [Accepted: 12/04/2020] [Indexed: 10/22/2022]
Abstract
AIMS To describe the impact of diabetes comorbidities on the health care services use and costs of a cohort of elderly patients with diabetes and high health care needs (HHCN), based on real-world data. METHODS We focused on a cohort of diabetic patients with HHCN belonging to Resource Utilization Bands 4 and 5 according to the Adjusted Clinical Group (ACG) system. Their comorbidities were assessed using the clinical diagnoses that the ACG system assigns to single patients by combining different information flows. Regression models were applied to analyze the associations between comorbidities and health care service use or costs, adjusting for age and sex. RESULTS Our analyses showed that all health care service usage measures (e.g. access to emergency care; number of outpatient visits) and the total annual costs and pharmacy costs are associated significantly with comorbidity class. Instead, no differences in hospitalization rates by comorbidity class were revealed. CONCLUSION The association between a larger number of comorbidities and higher total health care service usage and costs was seen mainly for primary care services. This underscores the need to strengthen primary care for today's aging and multimorbid population.
Collapse
Affiliation(s)
- Alessandra Buja
- Department of Cardiologic, Vascular, and Thoracic Sciences, and Public Health, University of Padua, Padova, Italy
| | - Riccardo Caberlotto
- School of Specialization in Hygiene, Preventive Medicine and Public Health, University of Padua, Padova, Italy
| | - Carlo Pinato
- Department of Cardiologic, Vascular, and Thoracic Sciences, and Public Health, University of Padua, Padova, Italy
| | - Simona Fortunata Mafrici
- School of Specialization in Hygiene, Preventive Medicine and Public Health, University of Padua, Padova, Italy
| | - Umberto Bolzonella
- School of Specialization in Hygiene, Preventive Medicine and Public Health, University of Padua, Padova, Italy
| | - Giulia Grotto
- School of Specialization in Hygiene, Preventive Medicine and Public Health, University of Padua, Padova, Italy.
| | - Tatjana Baldovin
- Department of Cardiologic, Vascular, and Thoracic Sciences, and Public Health, University of Padua, Padova, Italy
| | | | | | - Vincenzo Baldo
- Department of Cardiologic, Vascular, and Thoracic Sciences, and Public Health, University of Padua, Padova, Italy
| |
Collapse
|
4
|
Álvarez-Fernández C, Romero-Saldaña M, Álvarez-López C, Molina-Luque R, Molina-Recio G, Vaquero-Abellán M. Gender differences and health inequality: Evolution of cardiovascular risk in workers. ARCHIVES OF ENVIRONMENTAL & OCCUPATIONAL HEALTH 2021; 76:406-413. [PMID: 33625316 DOI: 10.1080/19338244.2021.1891017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
The aim was to find out if there are any such differences due to gender in a cohort of workers followed for ten years, comparing their lifestyles and following the evolution of the main cardiovascular risk factors (CVRF) and their impact on cardiovascular risk. An observational longitudinal study of 698 civil servants workers (186 women and 512 men) of a local government office from Córdoba (Spain), was conducted over the period 2003-2014. We compared the initial and final prevalence of physical activity, smoking, obesity, hypertension, metabolic syndrome and diabetes. Cardiovascular risk was also assessed using the REGICOR (Registre Gironí del Cor) and SCORE (Systematic Coronary Risk Evaluation) equations. There was a greater rise in the prevalence of hypertension and hypercholesterolemia in the cohort in women than in men (94.2% vs. 38% and 92% vs 21.1%), while the reduction in smoking also differed by gender (26.4% vs. 36.5%). It could be that since women present a lower cardiovascular risk profile, they are treated less or less effort is made to keep the risk factors low, resulting in a worse evolution of smoking, hypercholesterolemia and hypertension in women.
Collapse
Affiliation(s)
- C Álvarez-Fernández
- Department of Safety and Occupational Health, City Council of Cordoba, Cordoba, Spain
| | - M Romero-Saldaña
- Department of Nursing, Faculty of Medicine and Nursing, University of Cordoba, Cordoba, Spain
- Grupo Asociado de Investigación Estilos de vida, Innovación y Salud. Insituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain
| | | | - R Molina-Luque
- Grupo Asociado de Investigación Estilos de vida, Innovación y Salud. Insituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain
| | - G Molina-Recio
- Department of Nursing, Faculty of Medicine and Nursing, University of Cordoba, Cordoba, Spain
- Grupo Asociado de Investigación Estilos de vida, Innovación y Salud. Insituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain
| | - M Vaquero-Abellán
- Department of Nursing, Faculty of Medicine and Nursing, University of Cordoba, Cordoba, Spain
| |
Collapse
|
5
|
Freier C, Heintze C, Herrmann WJ. Prescribing and medical non-adherence after myocardial infarction: qualitative interviews with general practitioners in Germany. BMC FAMILY PRACTICE 2020; 21:81. [PMID: 32384915 PMCID: PMC7210678 DOI: 10.1186/s12875-020-01145-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Accepted: 04/15/2020] [Indexed: 12/19/2022]
Abstract
BACKGROUND An increasing prevalence of having survived a myocardial infarction increases the importance of medical secondary prevention. Although preventive medication reduces mortality, prescribing and adherence are known to be frequently insufficient. General practitioners are the most important prescriber. However, their perspective on prescribing and medical non-adherence following myocardial infarction has not yet been explored. Thus, the aim of this study was to explore the general practitioners' perspective on long-term care after myocardial infarction focussing on medical prevention. METHODS In this qualitative interview study we conducted episodic interviews with sixteen general practitioners from rural and urban surgeries in Germany. Framework analysis with focus on general practitioners' prescribing and patients' non-adherence was performed. RESULTS Almost all general practitioners reported following guidelines for myocardial infarction aftercare and prescribing the medication that was initiated in the hospital; however, they described deviating from guidelines because of drugs' side effects or patients' intolerances. Some questioned the benefits of medical secondary prevention for the oldest of patients. General practitioners perceived good adherence among their patients who had had an MI while they regarded their methods for assessing medical non-adherence as limited. They perceived diverse reasons for non-adherence, particularly side effects, patients' freedom from symptoms and patients' indifference to health. They attributed mainly negative characteristics, like lack of knowledge and understanding, to non-adherent patients. These characteristics contribute to the difficulty of convincing these patients to take medications as prescribed. General practitioners improved adherence by preventing side effects, explaining the medication's necessity, facilitating intake and involving patients in decision-making. However, about half of the general practitioners reported threatening their patients with negative consequences of non-adherence. CONCLUSIONS General practitioners should be aware that discharge medication can be insufficient and thus, should always check hospital recommendations for accordance with guideline recommendations. Improving physicians' communication skills and informing and motivating patients in an adequate manner, for example in simple language, should be an important goal in the hospital and the general practitioner setting. General practitioners should assess patients' motivations through motivational interviewing, which no general practitioner mentioned during the interviews, and talk with them about adherence and long-term treatment goals regularly.
Collapse
Affiliation(s)
- Christian Freier
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of General Practice, Charitéplatz 1, 10117, Berlin, Germany.
| | - Christoph Heintze
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of General Practice, Charitéplatz 1, 10117, Berlin, Germany
| | - Wolfram J Herrmann
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of General Practice, Charitéplatz 1, 10117, Berlin, Germany
- Münster School of Health, FH Münster - University of Applied Sciences, Leonardo Campus 8, 48149, Münster, Germany
| |
Collapse
|
6
|
Knopf H, Busch MA, Du Y, Grams D, Scheidt-Nave C, Sarganas G. [Secondary prevention of coronary heart disease in women and men in Germany from 1997-1999 and from 2008-2011-Trend analysis with two national health population surveys]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2019; 62:861-869. [PMID: 31187183 DOI: 10.1007/s00103-019-02975-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
BACKGROUND The benefit of medicines in the secondary prevention of coronary heart disease (CHD) has been demonstrated in women and men. However, gender-specific differences have been observed in the prescription of these medicines. Information on trends in prevalence use in women and men from population-based studies are still lacking. METHODS Data of people aged 40-79 years with CHD from the national health interview and examination surveys for adults in Germany from 1997-1999 (GNHIES98, n = 411) and from 2008-2011 (DEGS1, n = 440) were analyzed. Trend analyses via multivariable regression models, taking into account relevant covariables, were used to calculate the prevalence of medicine use in secondary prevention of CHD between GNHIES98 and DEGS1. The following groups were considered: antiplatelet, statins, beta-receptor blockers, agents acting on the renin-angiotensin system (RAS blocker), calcium-channel blockers, and nitrate. RESULTS In one decade, the prevalence had increased for antiplatelet (24.0% vs. 59.6%), statins (18.5% vs. 56.2%), beta-receptor blockers (24.7% vs. 65.5%), and RAS blockers (31.6% vs. 69.0%). The prevalence of calcium-channel blockers (33.3% vs. 20.5%) and nitrate (40.6% vs. 10.1%) had decreased. In GNHIES98, men were more likely to use RAS blockers. Significant gender differences were found in DEGS1 only for angiotensin-converting-enzyme (ACE) inhibitors. CONCLUSION This study showed an improvement in the use of drugs for the secondary prevention of CHD in both sexes.
Collapse
Affiliation(s)
- Hildtraud Knopf
- Abteilung für Epidemiologie und Gesundheitsmonitoring, Robert Koch-Institut, General-Pape-Str. 62-66, 12101, Berlin, Deutschland
| | - Markus A Busch
- Abteilung für Epidemiologie und Gesundheitsmonitoring, Robert Koch-Institut, General-Pape-Str. 62-66, 12101, Berlin, Deutschland
| | - Yong Du
- Abteilung für Epidemiologie und Gesundheitsmonitoring, Robert Koch-Institut, General-Pape-Str. 62-66, 12101, Berlin, Deutschland
| | - Daniel Grams
- Abteilung für Epidemiologie und Gesundheitsmonitoring, Robert Koch-Institut, General-Pape-Str. 62-66, 12101, Berlin, Deutschland
| | - Christa Scheidt-Nave
- Abteilung für Epidemiologie und Gesundheitsmonitoring, Robert Koch-Institut, General-Pape-Str. 62-66, 12101, Berlin, Deutschland
| | - Giselle Sarganas
- Abteilung für Epidemiologie und Gesundheitsmonitoring, Robert Koch-Institut, General-Pape-Str. 62-66, 12101, Berlin, Deutschland. .,DZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung) e. V., Berlin, Deutschland.
| |
Collapse
|
7
|
Venkatason P, Zaharan NL, Ismail MD, Wan Ahmad WA, Mahmood Zuhdi AS. Trends and variations in the prescribing of secondary preventative cardiovascular therapies for non-ST elevation myocardial infarction (NSTEMI) in Malaysia. Eur J Clin Pharmacol 2018; 74:953-960. [PMID: 29582106 PMCID: PMC5999133 DOI: 10.1007/s00228-018-2451-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Accepted: 03/19/2018] [Indexed: 12/26/2022]
Abstract
PURPOSE Information is lacking on prescribing of preventative cardiovascular pharmacotherapies for patients with non-ST elevation myocardial infarction (NSTEMI) in the Asian region. This study examined the prescribing rate of these pharmacotherapies, comparing NSTEMI to STEMI, and variations across demographics and clinical factors within the NSTEMI group in the multi-ethnic Malaysian population. METHODS This is a retrospective analysis of the Malaysian National Cardiovascular Disease Database-Acute Coronary Syndrome registry from year 2006 to 2013 (n = 30,873). On-discharge pharmacotherapies examined were aspirin, ADP-antagonists, statins, ACE-inhibitors, angiotensin-II-receptor blockers, and beta-blockers. Multivariate logistic regression was used to calculate adjusted odds ratio of receiving individual pharmacotherapies according to patients' characteristics in NSTEMI patients (n = 11,390). RESULTS Prescribing rates for cardiovascular pharmacotherapies had significantly increased especially for ADP-antagonists (76%) in NSTEMI patients. More than 85% were prescribed statins and antiplatelets but rates remained significantly lower compared to STEMI. Women and those over 65 years old were less likely to be prescribed these pharmacotherapies compared to men and younger NSTEMI patients. Chinese and Indians were more likely to receive selected pharmacotherapies compared to Malays (main ethnicity). Geographical variations were observed; East Malaysian (Malaysian Borneo) patients were less likely to receive these compared to Western region of Malaysian Peninsular. Underprescribing in patients with risk factors such as diabetes were observed with other co-morbidities influencing prescribing selectively. CONCLUSION This study uncovers demographic and clinical variations in cardiovascular pharmacotherapies prescribing for NSTEMI. Concerted efforts by policy makers, specialty societies, and physicians are required focusing on elderly, women, Malays, East Malaysians, and high-risk patients.
Collapse
Affiliation(s)
- Padmaa Venkatason
- Department of Medicine, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia
| | - Nur Lisa Zaharan
- Department of Pharmacology, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia
| | - Muhammad Dzafir Ismail
- Department of Medicine, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia
| | - Wan Azman Wan Ahmad
- Department of Medicine, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia
| | | |
Collapse
|
8
|
Heintjes E, Kuiper J, Lucius B, Penning-van Beest F, Kutikova L, Liem A, Herings R. Characterization and cholesterol management in patients with cardiovascular events and/or type 2 diabetes in the Netherlands. Curr Med Res Opin 2017; 33:91-100. [PMID: 27646783 DOI: 10.1080/03007995.2016.1239190] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
OBJECTIVE To describe clinical characteristics and cholesterol management of patients with cardiovascular events (CVEs) and/or type 2 diabetes mellitus (T2DM) with high low-density lipoprotein cholesterol (LDL-C) > 1.8 mmol/L in the Netherlands. RESEARCH DESIGN AND METHODS From the PHARMO Database Network a cross-sectional cohort was constructed. The descriptive study included patients on lipid modifying therapy (LMT) in 2009, classified as high cardiovascular risk based on a history of T2DM or CVE, with 2010 LDL-C levels above 1.8 mmol/L (2011 European Society of Cardiology [ESC] target). Sub-cohorts were created: T2DM + CVE from the T2DM cohort and multiple CVE from the CVE only cohort. MAIN OUTCOME MEASURES Clinical characteristics and drug treatment were determined at the time of the last LDL-C measurement in 2010. RESULTS Of 10,864 very high risk patients, 66% had T2DM, 37% of whom also had CVE. In the CVE only cohort (34%), 18% had multiple events. More regular check-ups skewed inclusion towards diabetes patients. T2DM vs. CVE cohort characteristics were: 53% vs. 63% male, 42% vs. 27% obese, 19% vs. 24% current smoker, 54% vs. 51% systolic blood pressure <140 mmHg, with similar proportions in the sub-cohorts. Proportions reaching the Dutch guideline LDL-C target of <2.5 mmol/L were 56% (T2DM), 57% (T2DM + CVE), 48% (CVE only) and 53% (multiple CVE only). Frequencies of high intensity dose statin (simvastatin ≥80 mg, atorvastatin ≥40 mg or rosuvastatin ≥20 mg) were 6% (T2DM), 9% (T2DM + CVE, CVE only) and 14% (multiple CVE only); 1-2% received additional ezetimibe and 3-5% received non-statin LMT only, including ezetimibe. CONCLUSION Despite LMT, >40% of the patients above ESC target also failed to reach the less stringent Dutch target, even in the higher risk groups. Therefore, management of hypercholesterolemia after CVE or T2DM should be optimized to improve cardiovascular outcomes. There is substantial room for improving other cardiovascular risk factors.
Collapse
Affiliation(s)
- Edith Heintjes
- a PHARMO Institute for Drug Outcomes Research , Utrecht , Netherlands
| | - Josephina Kuiper
- a PHARMO Institute for Drug Outcomes Research , Utrecht , Netherlands
| | - Bianca Lucius
- b Amgen BV , Dept. Value Access & Policy , Breda , Netherlands
| | | | - Lucie Kutikova
- c Amgen Europe , GmbH, Dept. Global Health Economics , Zug , Switzerland
| | - Anho Liem
- d Sint Franciscus Gasthuis , Dept. Cardiology , Rotterdam , Netherlands
| | - Ron Herings
- a PHARMO Institute for Drug Outcomes Research , Utrecht , Netherlands
| |
Collapse
|
9
|
|
10
|
Dodhia H, Kun L, Logan Ellis H, Crompton J, Wierzbicki AS, Williams H, Hodgkinson A, Balazs J. Evaluating quality and its determinants in lipid control for secondary prevention of heart disease and stroke in primary care: a study in an inner London Borough. BMJ Open 2015; 5:e008678. [PMID: 26656014 PMCID: PMC4679935 DOI: 10.1136/bmjopen-2015-008678] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
OBJECTIVES To assess quality of management and determinants in lipid control for secondary prevention of cardiovascular disease (CVD) using multilevel regression models. DESIGN Cross-sectional study. SETTING Inner London borough, with a primary care registered population of 378,000 (2013). PARTICIPANTS 48/49 participating general practices with 7869 patients on heart disease/stroke registers were included. OUTCOME MEASURES (1) Recording of current total cholesterol levels and lipid control according to national evidence-based standards. (2) Assessment of quality by age, sex, ethnicity, deprivation, presence of other risks or comorbidity in meeting both lipid measurement and control standards. RESULTS Some process standards were not met. Patients with a current cholesterol measurement >5 mmol/L were less likely to have a current statin prescription (adjusted OR=3.10; 95% CI 2.70 to 3.56). They were more likely to have clustering of other CVD risk factors. Women were significantly more likely to have raised cholesterol after adjustment for other factors (adjusted OR=1.74; 95% CI 1.53 to 1.98). CONCLUSIONS In this study, the key factor that explained poor lipid control in people with CVD was having no current prescription record of a statin. Women were more likely to have poorly controlled cholesterol (independent of comorbid risk factors and after adjusting for age, ethnicity, deprivation index and practice-level variation). Women with CVD should be offered statin prescription and may require higher statin dosage for improved control.
Collapse
Affiliation(s)
- Hiten Dodhia
- Lambeth & Southwark Councils, Public Health, London, UK
| | - Liu Kun
- Division of Health and Social Care Research, King's College London, London, UK
| | | | | | | | - Helen Williams
- NHS Southwark Clinical Commissioning Group,Medicines Management Team, LondonUK
| | - Anna Hodgkinson
- NHS Lambeth Clinical Commissioning Group, Medicines Management Team, London, UK
| | - John Balazs
- NHS Lambeth Clinical Commissioning Group, Governing Body Member, London, UK
| |
Collapse
|
11
|
Buja A, Damiani G, Gini R, Visca M, Federico B, Donato D, Francesconi P, Marini A, Donatini A, Brugaletta S, Baldo V, Donata Bellentani M. Systematic age-related differences in chronic disease management in a population-based cohort study: a new paradigm of primary care is required. PLoS One 2014; 9:e91340. [PMID: 24632818 PMCID: PMC3954692 DOI: 10.1371/journal.pone.0091340] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2013] [Accepted: 02/12/2014] [Indexed: 11/18/2022] Open
Abstract
Background Our interest in chronic conditions is due to the fact that, worldwide, chronic diseases have overtaken infectious diseases as the leading cause of death and disability, so their management represents an important challenge for health systems. The aim of this study was to compare the performance of primary health care services in managing diabetes, congestive heart failure (CHF) and coronary heart disease (CHD), by age group. Methods This population-based retrospective cohort study was conducted in Italy, enrolling 1,948,622 residents ≥16 years old. A multilevel regression model was applied to analyze compliance to care processes with explanatory variables at both patient and district level, using age group as an independent variable, and adjusting for sex, citizenship, disease duration, and Charlson index on the first level, and for District Health Unit on the second level. Results The quality of chronic disease management showed an inverted U-shaped relationship with age. In particular, our findings indicate lower levels for young adults (16–44 year-olds), adults (45–64), and oldest old (+85) than for patients aged 65–74 in almost all quality indicators of CHD, CHF and diabetes management. Young adults (16–44 y), adults (45–64 y), the very old (75–84 y) and the oldest old (+85 y) patients with CHD, CHF and diabetes are less likely than 65–74 year-old patients to be monitored and treated using evidence-based therapies, with the exceptions of echocardiographic monitoring for CHF in young adult patients, and renal monitoring for CHF and diabetes in the very old. Conclusion Our study shows that more effort is needed to ensure that primary health care systems are sensitive to chronic conditions in the young and in the very elderly.
Collapse
Affiliation(s)
- Alessandra Buja
- Laboratory of Public Health and Population Studies, Section Public Health, Dipartimento di Medicina Molecolare, Università di Padova, Padova, Italy
- * E-mail:
| | - Gianfranco Damiani
- Istituto di Sanità pubblica, Facoltà di Medicina, Università Cattolica Sacro Cuore di Roma, Roma, Italy
| | - Rosa Gini
- Osservatorio di Epidemiologia, Agenzia Regionale di Sanità della Toscana, Firenze, Italy
| | - Modesta Visca
- Sezione OSS - Organizzazione Servizi Sanitari, Agenas, Agenzia Nazionale per i Servizi Sanitari, Roma, Italy
| | - Bruno Federico
- Dipartimento di Scienze Umane, Sociali e della Salute, Università degli Studi di Cassino e del Lazio Meridionale, Cassino, Italy
| | | | - Paolo Francesconi
- Osservatorio di Epidemiologia, Agenzia Regionale di Sanità della Toscana, Firenze, Italy
| | | | | | | | - Vincenzo Baldo
- Laboratory of Public Health and Population Studies, Dipartimento di Medicina Molecolare, Università di Padova, Padova, Italy
| | - Maria Donata Bellentani
- Sezione OSS - Organizzazione Servizi Sanitari, Agenas, Agenzia Nazionale per i Servizi Sanitari, Roma, Italy
| |
Collapse
|